In vitro evaluation of an active heat-and-moisture exchanger: the Hygrovent Gold.

BACKGROUND: To improve the heat and humidification that can be achieved with a heat-and-moisture exchanger (HME), a hybrid active (ie, adds heat and water) HME, the Hygrovent Gold, was developed. We evaluated in vitro the performance of the Hygrovent Gold. METHODS: We tested the Hygrovent Gold (with and without its supplemental heat and moisture options activated), the Hygrobac, and the Hygrovent S. We measured the absolute humidity, using a test lung ventilated at minute volumes of 5, 10, and 15 L/min, in normothermic (expired temperature 34 degrees C) and hypothermic (expired temperature 28 degrees C) conditions. We also measured the HMEs' flow resistance and weight after 24 h and 48 h. RESULTS: In its active mode the Hygrovent Gold provided the highest absolute humidity, independent of minute volume, in both normothermia and hypothermia. The respective normothermia and hypothermia absolute humidity values at 10 L/min were 36.3 + 1.3 mg/L and 27.1 + 1.0 mg/L with the active Hygrovent Gold, 33.9 + 0.5 mg/L and 24.2 + 0.8 mg/L with the passive Hygrovent Gold, 33.8 + 0.56 mg/L and 24.4 + 0.4 mg/L with the Hygrobac, and 33.9 + 0.8 mg/L and 24.6 + 0.6 mg/L with the Hygrovent S. The efficiency of the tested HMEs did not change over time. At 24 h and 48 h the increase in weight and flow resistance was highest in the active Hygrovent Gold. CONCLUSIONS: The passive Hygrovent Gold provided adequate heat and moisture in normothermia, but the active Hygrovent Gold provided the highest humidity, in both normothermia and hypothermia.

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

OBJECTIVE: A systematic review was performed to compare the effectiveness and tolerability of lipid-based amphotericin B (AmB) formulations and conventional AmB in the treatment of systemic fungal infections. METHODS: The literature and unpublished studies were searched using MEDLINE, EMBASE, Biological Abstracts, AIDSLINE, CANCERLIT, CRD database, Cochrane Controlled Trials Register, and other databases. Search terms included: amphotericin, liposom*, lipid*, colloid*, antifungal agents, and mycoses. Studies were selected according to predetermined criteria. The outcome measures reviewed were efficacy, mortality, renal toxicity, and infusion-related reactions. Meta-analyses and number-needed-to-treat (NNT) analyses were performed. RESULTS: Seven studies (8 publications) met the entry criteria. Meta-analysis showed that lipid-based formulations significantly reduced all-cause mortality risk by an estimated 28% compared with conventional AmB (odds ratio [OR], 0.72; 95% CI, 0.54 to 0.97). There was no significant difference in efficacy between the lipid-based formulations and conventional AmB (OR, 1.21; 95% CI, 0.98 to 1.49). AmB lipid complex (ABLC) and liposomal AmB (L-AmB) significantly reduced the risk of doubling serum creatinine by an estimated 58% (OR, 0.42; 95% CI, 0.33 to 0.54). There was no significant reduction in risk of infusion-related reactions with lipid-based formulations, although this was difficult to interpret given the lack of consistent control of confounding factors. Comparing the lipid-based formulations with conventional AmB, the overall NNT to prevent 1 death was 31. The NNT to prevent a doubling of serum creatinine for both ABLC and L-AmB compared with conventional AmB was 6. CONCLUSIONS: This study demonstrates advantages with lipid-based formulations over conventional AmB in terms of reduced risk of mortality and renal toxicity. Future trials in patients with proven fungal infection should control for factors such as premedication, infusion rates, fluid preloading, sodium/potassium supplementation, and concomitant medication.